1. Home
  2. ARVN vs TRTX Comparison

ARVN vs TRTX Comparison

Compare ARVN & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$10.04

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Logo TPG RE Finance Trust Inc.

TRTX

TPG RE Finance Trust Inc.

HOLD

Current Price

$8.49

Market Cap

606.5M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
TRTX
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
658.2M
606.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ARVN
TRTX
Price
$10.04
$8.49
Analyst Decision
Buy
Buy
Analyst Count
19
4
Target Price
$15.05
$9.83
AVG Volume (30 Days)
640.4K
525.6K
Earning Date
05-04-2026
04-28-2026
Dividend Yield
N/A
11.55%
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
$8.78
Revenue Next Year
N/A
$4.14
P/E Ratio
N/A
$14.82
Revenue Growth
N/A
N/A
52 Week Low
$5.90
$7.44
52 Week High
$14.22
$9.85

Technical Indicators

Market Signals
Indicator
ARVN
TRTX
Relative Strength Index (RSI) 40.04 56.72
Support Level $9.96 $8.45
Resistance Level $10.18 $8.72
Average True Range (ATR) 0.55 0.19
MACD 0.03 0.02
Stochastic Oscillator 20.36 43.64

Price Performance

Historical Comparison
ARVN
TRTX

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About TRTX TPG RE Finance Trust Inc.

TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.

Share on Social Networks: